Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07288203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 76% 100 → 24 participants
See other at-risk trials from Iovance Biotherapeutics

Record History

  1. Enrollment reduced: 100 → 24 participants Primary completion moved earlier from Dec 2032 to Dec 2027 · Completion moved earlier from Dec 2033 to Jun 2028 · Eligibility criteria expanded, about 32 words · 3 more Show 6 more changesShow less
    • Primary completion moved earlier from Dec 2032 to Dec 2027
    • Completion moved earlier from Dec 2033 to Jun 2028
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 11 to 6
    • Study description revised
    • Site details revised at 1 of 5 sites
  2. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 5 of 5 sitesv3 Show 1 more changeShow less
    • Site details revised at 5 of 5 sites
  3. Study sites: 4 to 5v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Iovance Biotherapeutics
12 trials monitored
See 1 trial at risk
Melanoma
1,026 trials monitored
See 48 trials at risk
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Trial Details
NCT Number NCT07288203
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov